AACR 2021 | CROWN: biomarkers for lorlatinib response in patients with ALK+ NSCLC

The Phase III CROWN trial (NCT03052608) demonstrated a clinically meaningful improvement in progression-free survival (PFS) in patients with ALK+ non-small cell lung cancer (NSCLC) who were treated with lorlatinib, an ALK tyrosine kinase inhibitor, versus those treated with crizotinib. Alessandra Bearz, MD, of The CRO National Cancer Institute, Aviano, Italy, discusses the results of a study which performed molecular profiling on plasma and tissue samples from patients treated in the CROWN trial. Analysis found that based on pre-treatment circulating free DNA analysis, lorlatinib achieved similar clinical benefits regardless of the type of EML4-ALK variant or presence of ALK kinase mutations. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.